Geron to Present at Upcoming Investor Conferences
Geron says live and archived audio webcasts will be available on its website for its Sept. 9 and Sept. 15 investor-conference fireside chats.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Geron (GERN) will participate in two upcoming investor conferences in New York in September 2026.
The company will host a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 8:00 a.m. ET and at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, September 15, 2026, at 3:30 p.m. ET. Live and archived audio webcasts will be accessible via the Investor section of Geron’s website.
Details
News Market Reaction – GERN
On Sep 2, the day this news came out, GERN closed 7.43% above the previous close. Argus tracked a peak move of +5.2% during that session. Our momentum scanner recorded 25 alerts for this stock that day. Relative volume reached 3.7x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences:
- 2026 Cantor Global Healthcare Conference:
Fireside Chat on Wednesday, September 9, 2026, at 8:00 a.m. ET in New York, NY
- H.C. Wainwright 28th Annual Global Investment Conference:
Fireside Chat on Tuesday, September 15, 2026, at 3:30 p.m. ET in New York, NY
Live and archived audio webcasts of the fireside chats will be available through the Investor section of Geron’s website at www.geron.com.
About Geron
Geron is a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer. Because patients cannot wait, we approach our work with urgency, bringing together deep expertise in telomerase biology with patient perspectives and insights from clinical research and real-world care. Our medicine, RYTELO® (imetelstat), is approved in the United States and European Union for certain patients with lower-risk myelodysplastic syndromes (LR-MDS). We are building on our foundation in telomerase inhibition by studying imetelstat in myelofibrosis, including a pivotal Phase 3 clinical trial in patients with JAK-inhibitor relapsed/refractory disease, as well as other hematologic malignancies. Geron is a commercial-stage company with offices in Parsippany, New Jersey and Foster City, California. To learn more, visit www.geron.com or follow us on LinkedIn.
Investors and Media
Dawn Schottlandt
Senior Vice President, Investor Relations and Corporate Affairs
dschottlandt@geron.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.